NRX Pharmaceuticals Inc (NASDAQ:NRXP) has a beta value of 1.46 and has seen 1.35 million shares traded in the recent trading session. The company, currently valued at $36.52M, closed the recent trade at $2.12 per share which meant it gained $0.04 on the day or 1.92% during that session. The NRXP stock price is -183.49% off its 52-week high price of $6.01 and 48.11% above the 52-week low of $1.10.
The consensus among analysts is that NRX Pharmaceuticals Inc (NRXP) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.25.
NRX Pharmaceuticals Inc (NASDAQ:NRXP) trade information
Sporting 1.92% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the NRXP stock price touched $2.12 or saw a rise of 1.4%. Year-to-date, NRX Pharmaceuticals Inc shares have moved -3.64%, while the 5-day performance has seen it change 10.42%. Over the past 30 days, the shares of NRX Pharmaceuticals Inc (NASDAQ:NRXP) have changed 3.41%.
Wall Street analysts have a consensus price target for the stock at $2, which means that the shares’ value could drop -6.0% from the levels at last check today.. The projected low price target is $2.0 while the price target rests at a high of $2.0. In that case, then, we find that the latest price level in today’s session is 5.66% off the targeted high while a plunge would see the stock lose 5.66% from the levels at last check today..
NRX Pharmaceuticals Inc (NRXP) estimates and forecasts
The company’s shares have gained 63.08% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
2 have an estimated revenue figure of 500k for the next ending quarter.
NRXP Dividends
NRX Pharmaceuticals Inc is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Also the top two Mutual Funds that are holding company’s shares are AdvisorShares Trust-AdvisorShares Psychedelics ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 1.67% shares in the company for having 286.8 shares of worth $0.63 million while later fund manager owns 193.42 shares of worth $0.42 million as of Dec 31, 2024 , which makes it owner of about 1.12% of company’s outstanding stock.
